Nasus Pharma Ltd. (NYSE: NSRX) will showcase its clinical-stage pharmaceutical portfolio across three prominent investor conferences over the next month. Chief Executive Officer Dan Teleman is scheduled to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, followed by presentations at the BIO Investment & Growth Summit on March 2 and the Citizens Life Sciences Conference on March 3.
The clinical-stage company is advancing NS002, an intranasal powder formulation of Epinephrine designed to provide a needle-free alternative to traditional autoinjectors for the emergency treatment of anaphylaxis. This therapeutic approach addresses a significant gap in the current treatment landscape by offering patients a non-injectable delivery mechanism for rapid anaphylaxis intervention.
The conference presentations will provide investors and industry stakeholders with insights into Nasus Pharma's clinical development strategy and the commercial potential of its intranasal product platform. These investor engagements underscore the company's commitment to communicating its pipeline progress to the financial and healthcare investment communities.